Impavido attenuates inflammation, reduces atherosclerosis, and alters gut microbiota in hyperlipidemic mice.
Sign Up to like & getrecommendations! Published in 2023 at "iScience"
DOI: 10.2139/ssrn.4201712
Abstract: Impavido (Miltefosine) is an FDA-approved drug for treating leishmaniasis and primary amebic meningoencephalitis. We have shown previously that Miltefosine increased cholesterol release and dampened Nlrp3 inflammasome assembly in macrophages. Here, we show that Miltefosine reduced… read more here.
Keywords: inflammation; gut microbiota; miltefosine fed; atherosclerosis ... See more keywords